CD147 knockdown improves the antitumor efficacy of trastuzumab in HER2-positive breast cancer cells

Trastuzumab is widely used in the clinical treatment of human epidermal growth factor receptor-2 (HER2)-positive breast cancer, but the patient response rate is low. CD147 stimulates cancer cell proliferation, migration, metastasis and differentiation and is involved in chemoresistance in many types...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Lijuan, Ding, Li, Ning, Haoyong, Wu, Chenglin, Fu, Kaifei, Wang, Yuxiao, Zhang, Yan, Liu, Yan, Zhou, Lijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295386/
https://www.ncbi.nlm.nih.gov/pubmed/27363028
http://dx.doi.org/10.18632/oncotarget.10252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295386/
https://www.ncbi.nlm.nih.gov/pubmed/27363028
http://dx.doi.org/10.18632/oncotarget.10252

Ejemplares similares